Arrayit Corporation (OTCBB:
) announced today that it has sold a third advanced microarray manufacturing system to the University of Texas Southwestern Medical Center at Dallas. The NanoPrint LM60 Microarrayer equipped with Arrayit's Patented Microarray Manufacturing Technology (US Patent 6,101,946) is a computer-driven robotic microarray manufacturing system that enables the screening of 1.5 million lead therapeutic compounds per run, and the NanoPrint LM210 enables more than 5 million. UT Southwestern will use the NanoPrint LM60 to screen large libraries of potential therapeutic small molecules involved in cancer and heart disease. These small molecules have advantageous stability and biological activity, are suitable for drug delivery, and are easily manufactured in large, diverse libraries, making them attractive for therapeutic use. The use of Arrayit's technology and UT Southwestern's systematic approach has already led to the discovery of specific compounds known to be involved in cancer and cardiovascular disease.
Once an Arrayit manufacturing platform is installed, customers purchase an ongoing supply of proprietary consumable products. More than 800 items are featured in the company’s catalog enabling applications in small molecule high throughput screening, gene expression, multiplexed immunoassays, cytogenetics and more. According to Mr. Todd Martinsky, Executive Vice President of Arrayit Corporation, the company’s proprietary microarray manufacturing technology has been installed at more than 3,800 institutions worldwide. Arrayit brand products are distributed in 43 countries and are regularly used by more than 10,000 research laboratories. Twenty-seven institutions in Texas use Arrayit Technology, including Baylor College of Medicine, Lamar University, MD Anderson, Prairie View A&M, Rice University, Stephen F. Austin State University, Texas A&M, Texas Tech, UT Arlington, UT Austin, UT Houston, UT San Antonio and the VA Medical Center. The base price for the NanoPrint LM60 system is about $125,000.
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Please visit
for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2010 and Form 10-Q for the fiscal quarters ended March 31, 2010 and June 30, 2010.